Kestra Medical secures $200m non-dilutive loan facility with Pharmakon
Kestra Medical Technologies has entered into a five-year term loan facility with funds managed by Pharmakon Advisors, providing up to $200 million in non-dilutive financing. The Kirkland, Washington-based company, which makes wearable cardiovascular monitoring and intervention devices, said the deal strengthens its balance sheet and replaces an existing $45 million term loan that has now been retired.
The facility is structured in tranches. An initial $75 million was drawn at closing, part of which retired the prior loan and covered fees. A further $25 million is available at Kestra's option through July 2027, and $50 million more becomes accessible through June 2028 subject to the company generating $150 million in trailing twelve-month revenue. A fourth, uncommitted $50 million tranche is reserved for acquisitions, requiring Pharmakon's consent before it can be drawn.
Deal structure and cost of capital
The loan carries 48 months of interest-only payments, extendable by a further twelve months on satisfaction of a revenue milestone. Interest accrues quarterly at three-month SOFR plus 5.5 percentage points, with a SOFR floor of 3.25%. At current SOFR levels the effective rate sits in the high single digits, broadly in line with recent life sciences debt transactions of this type, though precise comparisons depend on Kestra's credit profile and covenant terms.
Brian Webster, president and chief executive, said the financing "fortifies Kestra's balance sheet, reduces the company's cost of capital, and provides us significant financial flexibility." He added that the company intends to continue investing in growth, citing what he described as strong commercial momentum and attractive unit economics.
As of 30 April 2026, Kestra reported cash and investments of $262 million. Including undrawn tranches under the new facility (but excluding the uncommitted acquisition tranche), total available liquidity now stands at approximately $357 million. Armentum Partners advised Kestra on the transaction, and full terms will be filed with the SEC in a Form 8-K.
Market context
Non-dilutive debt financing has become an increasingly popular route for commercial-stage medical device companies seeking to fund growth without issuing equity. Pharmakon Advisors, the lender here, has deployed $12.7 billion across 81 life sciences investments since its founding in 2009, making it one of the more active specialist creditors in the sector. Its participation signals reasonable confidence in Kestra's near-term revenue trajectory.
The wearable cardiac device market is competitive, with established players in remote monitoring and implantable solutions pressing into adjacent wearable categories. Kestra's commercial focus on cardiovascular disease places it in a segment where reimbursement coverage and clinical adoption rates are critical levers. The revenue milestone attached to the third tranche, $150 million in trailing twelve-month sales, will be closely watched by investors as a de facto forward indicator of the company's commercial progress.
With a material liquidity cushion now in place and no near-term equity dilution, Kestra has room to pursue organic growth and, per the acquisition tranche, bolt-on deals if the right targets emerge.